Brian J McMahon1, Lisa Bulkow2, Brenna Simons3, Yuhong Zhang4, Susan Negus3, Chriss Homan3, Philip Spradling5, Eyasu Teshale5, Daryl Lau4, Mary Snowball3, Stephen E Livingston6. 1. Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska; Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention (CDC), Anchorage, Alaska. 2. Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention (CDC), Anchorage, Alaska. 3. Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska. 4. Division of Gastroenterology/Liver Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. 5. Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia. 6. Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska. Electronic address: slivings@anthc.org.
Abstract
BACKGROUND & AIMS: There is little information on the proportion of persons with chronic hepatitis B virus (HBV) infection with active hepatitis. We aimed to determine the proportion of persons with hepatitis B e antigen-negative chronic HBV infection who develop immune-active HBV infection over time and the relationship between demographic and viral factors on severity of disease on liver biopsy. METHODS: We performed a longitudinal population-based cohort study of 754 Alaska Native patients with chronic HBV infection. Levels of alanine aminotransferase (ALT) were measured every 6 months, and levels of HBV DNA were measured at study entry and whenever ALT levels exceeded the upper limit of normal (ULN). Immune-active chronic HBV infection was defined as levels of ALT ≥ 30 U/L in men and >20 U/L in women and levels of HBV DNA >2000 IU/mL at 1 or more time points from 2001-2008. Liver biopsies were scored by using the modified histology activity index score of Knodell and the Ishak fibrosis score. RESULTS: Of the study participants, 186 (25%) met the criteria for immune-active HBV, 56% of these initially and 44% later during follow up. Of the 38 patients with liver biopsy results, only 1 of 16 with ALT levels consistently below twice the ULN and 1 of 19 with HBV DNA between 2000 and 20,000 IU/mL, vs 12 of 22 (55%) with ALT > twice ULN (P = .002) and 11 of 18 (61%) with 1 or more measurements of HBV DNA >20,000 IU/mL (P < .001), had moderate or severe hepatitis or fibrosis. CONCLUSIONS: In a cohort of Alaska Natives with chronic HBV infection, 25% met criteria for immune-active HBV. There is a low probability of advanced fibrosis if levels of HBV DNA never exceed 20,000 IU/mL.
BACKGROUND & AIMS: There is little information on the proportion of persons with chronic hepatitis B virus (HBV) infection with active hepatitis. We aimed to determine the proportion of persons with hepatitis B e antigen-negative chronic HBV infection who develop immune-active HBV infection over time and the relationship between demographic and viral factors on severity of disease on liver biopsy. METHODS: We performed a longitudinal population-based cohort study of 754 Alaska Native patients with chronic HBV infection. Levels of alanine aminotransferase (ALT) were measured every 6 months, and levels of HBV DNA were measured at study entry and whenever ALT levels exceeded the upper limit of normal (ULN). Immune-active chronic HBV infection was defined as levels of ALT ≥ 30 U/L in men and >20 U/L in women and levels of HBV DNA >2000 IU/mL at 1 or more time points from 2001-2008. Liver biopsies were scored by using the modified histology activity index score of Knodell and the Ishak fibrosis score. RESULTS: Of the study participants, 186 (25%) met the criteria for immune-active HBV, 56% of these initially and 44% later during follow up. Of the 38 patients with liver biopsy results, only 1 of 16 with ALT levels consistently below twice the ULN and 1 of 19 with HBV DNA between 2000 and 20,000 IU/mL, vs 12 of 22 (55%) with ALT > twice ULN (P = .002) and 11 of 18 (61%) with 1 or more measurements of HBV DNA >20,000 IU/mL (P < .001), had moderate or severe hepatitis or fibrosis. CONCLUSIONS: In a cohort of Alaska Natives with chronic HBV infection, 25% met criteria for immune-active HBV. There is a low probability of advanced fibrosis if levels of HBV DNA never exceed 20,000 IU/mL.
Authors: H Yotsuyanagi; K Yasuda; S Iino; K Moriya; Y Shintani; H Fujie; T Tsutsumi; S Kimura; K Koike Journal: Hepatology Date: 1998-05 Impact factor: 17.425
Authors: K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween Journal: J Hepatol Date: 1995-06 Impact factor: 25.083
Authors: R G Knodell; K G Ishak; W C Black; T S Chen; R Craig; N Kaplowitz; T W Kiernan; J Wollman Journal: Hepatology Date: 1981 Sep-Oct Impact factor: 17.425
Authors: Brian J McMahon; Dana Bruden; Lisa Townshend-Bulson; Brenna Simons; Phillip Spradling; Stephen Livingston; James Gove; Annette Hewitt; Julia Plotnik; Chriss Homan; Hannah Espera; Susan Negus; Mary Snowball; Youssef Barbour; Michael Bruce; Prabhu Gounder Journal: Clin Gastroenterol Hepatol Date: 2016-10-17 Impact factor: 11.382
Authors: P P Gounder; L R Bulkow; M Snowball; S Negus; P R Spradling; B C Simons; B J McMahon Journal: Aliment Pharmacol Ther Date: 2016-04-08 Impact factor: 8.171
Authors: Hye Kyong Park; Sang Soo Lee; Chang Bin Im; Changjo Im; Ra Ri Cha; Wan Soo Kim; Hyun Chin Cho; Jae Min Lee; Hyun Jin Kim; Tae Hyo Kim; Woon Tae Jung; Ok-Jae Lee Journal: BMC Cancer Date: 2019-08-20 Impact factor: 4.430
Authors: Valter Oberdan Borges de Oliveira; Juliana Passos Rocha Oliveira; Eloy Vianey Carvalho de França; Hugo Leite de Farias Brito; Tereza Virgínia Nascimento; Alex França Journal: Rev Inst Med Trop Sao Paulo Date: 2016-09-22 Impact factor: 1.846